Literature DB >> 8156508

Gastric mucosal injury after hepatic arterial infusion chemotherapy with floxuridine. A clinical and pathologic study.

M I Doria1, L K Doria, J Faintuch, B Levin.   

Abstract

BACKGROUND: Hepatic arterial infusion chemotherapy (HAIC) of liver metastases of colon cancer with an implantable pump is associated with liver and gastrointestinal complications.
METHODS: The authors retrospectively studied the clinical features and gastric histopathology of nine patients who received HAIC and had gastritis develop and in whom biopsy specimens were available.
RESULTS: Gastritis was heralded in these patients by epigastric pain and tenderness, nausea, vomiting, weakness, and anorexia. In seven patients, 18 gastric ulcers were endoscopically detected. Mucosal damage developed despite prophylactic antiulcer therapy and healed only upon cessation of HAIC. These observations suggest that the predominant drug given, floxuridine, was the responsible toxic agent. Seventeen biopsy specimens were reviewed, and all exhibited varied histologic evidence of inflammation, reactive glandular changes, and cell necrosis. These mucosal changes were present even in tissues obtained from patients without ulcers. In addition, floxuridine-induced glandular atypia was noted in eight biopsy samples from six patients. The crowded glands were distorted and lined by large cells that included bizarre forms with pleomorphic nuclei.
CONCLUSIONS: Gastric injury in HAIC appeared analogous to the general features encountered in reactive gastritis resulting from chemical irritants. The glandular atypia is peculiar to HAIC, and although the changes were morphologically alarming, in this clinical situation care should be exercised not to interpret floxuridine-induced atypia as carcinoma.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8156508     DOI: 10.1002/1097-0142(19940415)73:8<2042::aid-cncr2820730805>3.0.co;2-a

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  7 in total

1.  Embolisation of the right gastric artery in patients undergoing hepatic arterial infusion chemotherapy using two possible approach routes.

Authors:  T Yamagami; K Terayama; R Yoshimatsu; T Matsumoto; H Miura; T Nishimura
Journal:  Br J Radiol       Date:  2010-05-04       Impact factor: 3.039

Review 2.  Pathology of non-Helicobacter pylori gastritis: extending the histopathologic horizons.

Authors:  Gregory Y Lauwers; Hiroshi Fujita; Koji Nagata; Michio Shimizu
Journal:  J Gastroenterol       Date:  2009-12-05       Impact factor: 7.527

3.  Gastroduodenal ulceration following hepatic arterial chemotherapy: the role of methylene blue endoscopy in the investigation of pain.

Authors:  M L Talbot; J R Clark; P C Clingan; D L Morris
Journal:  HPB (Oxford)       Date:  2002       Impact factor: 3.647

4.  Interventional management of gastroduodenal lesions complicating intra-arterial hepatic chemotherapy.

Authors:  Stefania Proietti; Thierry De Baere; Bertrand Bessoud; Francesco Doenz; Salah Dine Qanadli; Pierre Schnyder; Alban Denys
Journal:  Eur Radiol       Date:  2007-01-12       Impact factor: 7.034

5.  Retrograde embolization technique of the right gastric artery during the implantation of port-catheter system for hepatic arterial infusion chemotherapy.

Authors:  Jungang Hu; Guang Cao; Liang Xu; Kanglian Zheng; Xu Zhu; Renjie Yang; Xiao Wang; Xiaodong Wang
Journal:  J Interv Med       Date:  2020-10-12

6.  Evaluation of Various Nuclear Cytological Changes in Normal Buccal Mucosa and Peritumoural Area in Patients with Oral Squamous Cell Carcinoma Receiving Concomitant Chemoradiotherapy.

Authors:  Sadia Minhas; Muhammad Kashif; A H Nagi
Journal:  Patholog Res Int       Date:  2016-04-11

Review 7.  Effective and safe proton pump inhibitor therapy in acid-related diseases - A position paper addressing benefits and potential harms of acid suppression.

Authors:  Carmelo Scarpignato; Luigi Gatta; Angelo Zullo; Corrado Blandizzi
Journal:  BMC Med       Date:  2016-11-09       Impact factor: 8.775

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.